Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total value of $532,600.00. Following the completion of the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at $9,254,244.56. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Halozyme Therapeutics Price Performance
Shares of NASDAQ HALO traded down $0.36 during trading on Wednesday, reaching $53.46. The company had a trading volume of 932,298 shares, compared to its average volume of 1,287,925. The company has a current ratio of 7.41, a quick ratio of 6.21 and a debt-to-equity ratio of 5.19. Halozyme Therapeutics, Inc. has a twelve month low of $32.83 and a twelve month high of $65.53. The stock has a 50-day moving average price of $58.80 and a two-hundred day moving average price of $51.04. The stock has a market capitalization of $6.80 billion, a PE ratio of 22.05, a price-to-earnings-growth ratio of 0.49 and a beta of 1.27.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.18. The firm had revenue of $231.40 million during the quarter, compared to the consensus estimate of $204.94 million. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.68 EPS. As a group, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current year.
Hedge Funds Weigh In On Halozyme Therapeutics
Wall Street Analyst Weigh In
Several analysts recently commented on the stock. Morgan Stanley raised their price objective on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. The Goldman Sachs Group upped their price target on Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a report on Monday, July 22nd. Wells Fargo & Company cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price objective for the stock from $58.00 to $62.00 in a report on Monday, October 7th. Finally, TD Cowen upped their target price on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $60.44.
Check Out Our Latest Stock Analysis on Halozyme Therapeutics
About Halozyme Therapeutics
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Further Reading
- Five stocks we like better than Halozyme Therapeutics
- Investing In Preferred Stock vs. Common Stock
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- What is a SEC Filing?
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.